No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
AKRO240517C15000
- 4.60
- -1.28-21.77%
15min DelayClose May 17 15:58 ET
5.35High4.60Low
5.30Open5.88Pre Close23 Volume66 Open Interest15.00Strike Price12.10KTurnover4268.86%IV3.41%PremiumMay 17, 2024Expiry Date4.92Intrinsic Value100Multiplier0DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type0.8404Delta0.0354Gamma3.56Leverage Ratio-35.3820Theta0.0000Rho2.99Eff Leverage0.0004Vega
Intraday
- 5D
- 1D
News
Akero Therapeutics Is Maintained at Outperform by Evercore ISI Group
Akero Therapeutics Is Maintained at Outperform by Evercore ISI Group
Evercore ISI Group Maintains Outperform on Akero Therapeutics, Lowers Price Target to $38
Evercore ISI Group analyst Liisa Bayko maintains Akero Therapeutics (NASDAQ:AKRO) with a Outperform and lowers the price target from $50 to $38.
Express News | Akero Therapeutics Inc : Evercore ISI Cuts Target Price to $38 From $50
Akero Therapeutics Price Target Cut to $56.00/Share From $59.00 by Canaccord Genuity
Akero Therapeutics Price Target Cut to $56.00/Share From $59.00 by Canaccord Genuity
Akero Therapeutics Is Maintained at Buy by Canaccord Genuity
Akero Therapeutics Is Maintained at Buy by Canaccord Genuity
Insiders Could Have Profited By Holding Onto Akero Therapeutics Shares Despite 11% Drop
Akero Therapeutics, Inc.'s (NASDAQ:AKRO) value has fallen 11% in the last week, but insiders who sold US$4.7m worth of stock over the last year have had less success. Insiders might have been better
Comments
» Holdings: 87
» Holdings in Top 20: 86.71%
» Qtr over Qtr Change**: -9.29%
Top Holdings:
$Incyte(INCY.US$
$BeiGene(BGNE.US$
$ACADIA Pharmaceuticals(ACAD.US$
$Madrigal Pharmaceuticals(MDGL.US$
$Rhythm Pharmaceuticals(RYTM.US$
$Revolution Medicines(RVMD.US$
$Kymera Therapeutics(KYMR.US$
$AbCellera Biologics(ABCL.US$
$Bicycle Therapeutics(BCYC.US$
$Edgewise Therapeutics(EWTX.US$
$Immunocore(IMCR.US$
$Kodiak Sciences(KOD.US$
$Roivant Sciences(ROIV.US$
...
» Holdings in Top 20: 86.71%
» Qtr over Qtr Change**: -9.29%
Top Holdings:
$Incyte(INCY.US$
$BeiGene(BGNE.US$
$ACADIA Pharmaceuticals(ACAD.US$
$Madrigal Pharmaceuticals(MDGL.US$
$Rhythm Pharmaceuticals(RYTM.US$
$Revolution Medicines(RVMD.US$
$Kymera Therapeutics(KYMR.US$
$AbCellera Biologics(ABCL.US$
$Bicycle Therapeutics(BCYC.US$
$Edgewise Therapeutics(EWTX.US$
$Immunocore(IMCR.US$
$Kodiak Sciences(KOD.US$
$Roivant Sciences(ROIV.US$
...
5
$Akero Therapeutics(AKRO.US$ Im done with medical stocks not a single one of these companies can make good decisions
$Akero Therapeutics(AKRO.US$ MILWAUKEE, April 2, 2024 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against Akero (Nasdaq: AKRO). The investigation results from inaccurate statements Akero may have made regarding its business operations and prospects.
Click here to learn more about the investigation: or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.
The investigation focuses on Akero's representations...
Click here to learn more about the investigation: or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.
The investigation focuses on Akero's representations...
$Akero Therapeutics(AKRO.US$ this been falling everday smh
Read more